Announcement PDF ASX Announcement 4 March 2025 Investor Webinar: A deep dive on Microba’s Testing Business & Investor Newsletter Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company), a company at the forefront of microbiome diagnostics & therapeutics, is pleased to announce the first of a series of investor ‘deep dive’ webinars. These webinars aim to provide investors with a detailed understanding of the Company’s strategy, operations and global opportunity. Investor Webinar: The Evolution of the Testing Business The first deep dive webinar will focus on Microba’s Testing Business, providing insights into the evolution of its products and business models. Investors will hear from key members of Microba’s global leadership team, including: • • • Dr Luke Reid – Chief Executive Officer Eric Davis – Chief Growth Officer Chris Saad – Chief Product Officer Webinar details: • • • • Date: Thursday, 20 March Time: 11:00 AM AEDT | 10:00 AM AEST Platform: Zoom Duration: ~90 minutes (including live Q&A) Registration: Investors and interested parties can pre-register for the webinar via the following link: https://us02web.zoom.us/webinar/register/WN_cCE7UNnHQbu8KQsz2WgwLA Further webinars will be scheduled in the coming months, covering other important aspects of Microba’s business. Investor Newsletter Additionally, Microba has today published its inaugural Investor Newsletter which can be accessed here https://ir.microba.com/activity-updates, investors can subscribe to receive the newsletter via Microba’s Investor Hub by clicking here https://ir.microba.com/auth/signup. JOIN MICROBA’S INTERACTIVE INVESTOR HUB For more Company information and to engage with management by asking questions about Microba’s latest announcements and updates, visit ir.microba.com/welcome Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621 ASX Announcement 4 March 2025 This announcement has been authorised for release by the Chair & Chief Executive Officer. For further information, please contact: Dr Luke Reid Chief Executive Officer luke.reid@microba.com Investor / Media Relations investor@microba.com https://ir.microba.com/welcome About Microba Life Sciences Limited Microba Life Sciences is a company at the forefront of microbiome diagnostics & therapeutics and are on a mission to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com JOIN MICROBA’S INTERACTIVE INVESTOR HUB For more Company information and to engage with management by asking questions about Microba’s latest announcements and updates, visit ir.microba.com/welcome Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621